AbCellera Biologics Inc (ABCL) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund adding versus the previous quarter. Insiders were net buyers over the last 90 days ($1.4M bought vs $0 sold). Latest close $11.02 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 13, 2026 · Congress to Nov 16, 2026.
Baker Bros. Advisors — 1 tracked fund hold ABCL. See all holders.
Insiders bought on the open market (3 purchases, $1.4M) vs 0 sales ($0). Latest buy: Nov 13, 2026. Insider trading
No closely related stocks by co-holding for this stock. Browse all stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Baker Bros. Advisors | 1.30% | 33,012,138 | ADDED (+9.0%) Q3 filed Nov 16 |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: +45.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 149 of 8,857 filers |
| Long-only filers among them | 149 |
| Change vs 2026 Q1 | +13 net · 147 entered · 134 exited |
| Shares reported, all filers | 115,980,336 |
| Reported value, all filers | $936.5M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $75.1M |
| Net income · FY2025 | $-146.4M |
| Total assets · FY2025 | $1.4B |
| Shares outstanding | 306,611,466 |
| Market cap (at latest close) | $3.4B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.
| Shares short · Oct 15, 2026 | 30,934,912 |
| Share of shares outstanding | 10.09% |
| Days to cover | 5.63 |
Shares short at recent settlements — Jul 31, 2026: 48.3M · Aug 14, 2026: 41.3M · Aug 31, 2026: 34.8M · Sep 15, 2026: 33.9M · Sep 30, 2026: 32.5M · Oct 15, 2026: 30.9M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 321K · Aug 31, 2026: 0 · Sep 15, 2026: 2K · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.
3 insiders bought on the open market in the last 90 days (3 purchases, $1.4M), against 0 sales by 0 insiders ($0). Latest buy: Nov 13, 2026.
CEO/CFO boughtSource: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| Booth Andrew · 8,600 shares on Nov 13, 2026 · filed Nov 13, 2026 | $11.33 | -0.8% (close Nov 16, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Nov 16, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Booth Andrew | Chief Financial Officer | Buy | 8,600 | $11.33 | $97.4K | SEC filing |
| Nov 12, 2026 | Thermopylae Holdings Ltd. | Buy | 60,565 | $11.54 | $698.9K | SEC filing | |
| Aug 24, 2026 | Hayden Michael R | Buy | 53,613 | $10.64 | $570.4K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| May 7, 2026 | Baker Bros. Advisors LP | SC 13G/A | 33,012,138 | 10.8% | Apr 30, 2026 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).
Federal contracts: $884.0K in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $0 |
| FY2022 | $196.0K |
| FY2023 | $492.0K |
| FY2024 | $196.0K |
| FY2025 | $0 |
| FY2026 | $0 |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| 75D30122C14450 | Department of Health and Human Services | $884.0K | Aug 3, 2022 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Insiders
· Insider Cluster Buying — Last 90 days: 3 or more different insiders bought on the open market
· CEO & CFO Buying — Last 90 days: top executives (CEO/CFO) bought on the open market
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
· Opportunistic Buys (Non-Routine) — Last 90 days: 2 or more insiders with no routine buying pattern bought on the open market
Chart Signals
· Monthly Uptrend — Price above its 12-month moving average
· Top Relative Strength — Top 20% of the universe by 6-month return
Red Flags
· Auditor Change (8-K 4.01) — Last 2 years: an auditor change filing (8-K Item 4.01)
Key figures
· Insider Cluster Buying — Insiders buying: 3 · Buy txns: 3 · Buy value: $1.4M · Latest buy: Nov 13, 2026
· CEO & CFO Buying — Buy txns: 3 · Buy value: $1.4M · Insiders buying: 3 · Latest buy: Nov 13, 2026
· Insider Net Buying — Buy txns: 3 · Sell txns: 0 · Buy value: $1.4M · Latest buy: Nov 13, 2026
· Opportunistic Buys (Non-Routine) — Opportunistic buyers: 3 · Buy txns: 4 · Buy value: $1.5M · Latest buy: Aug 24, 2026
· Auditor Change (8-K 4.01) — Latest event: Nov 28, 2025 · Events in 2 yrs: 1
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 4 of the last 20 quarterly lists; latest 2023 Q3, ranked #45 of 50.
Moat analysis of AbCellera Biologics Inc on BlitzLab
| Filed | Items | Source |
|---|---|---|
| Nov 9, 2026 | 2.02 Results of Operations and Financial Condition · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 13, 2026 | 1.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Aug 10, 2026 | 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Stocks A–Z · Track Record: how the signals scored · Practice timing on ABCL
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.